Rosiglitazone‐activated PPARγ Induces Neurotrophic Factor‐α1 Transcription Contributing to Neuroprotection

Erwan Thouennon,Yong Cheng,Vida Falahatian,Niamh X. Cawley,Yoke Peng Loh

DOI: https://doi.org/10.1111/jnc.13152

2015-01-01

Journal of Neurochemistry

Abstract:Brain peroxisome proliferator-activated receptor gamma (PPAR), a member of the nuclear receptor superfamily of ligand-dependent transcription factors, is involved in neuroprotection. It is activated by the drug rosiglitazone, which then can increase the pro-survival protein B-cell lymphoma 2 (BCL-2), to mediate neuroprotection. However, the mechanism underlying this molecular cascade remains unknown. Here, we show that the neuroprotective protein neurotrophic factor-1 (NF-1), which also induces the expression of BCL-2, has a promoter that contains PPAR-binding sites that are activated by rosiglitazone. Treatment of Neuro2a cells and primary hippocampal neurons with rosiglitazone increased endogenous NF-1 expression and prevented H2O2-induced cytotoxicity. Concomitant with the increase in NF-1, BCL-2 was also increased in these cells. When siRNA against NF-1 was used, the induction of BCL-2 by rosiglitazone was prevented, and the neuroprotective effect of rosiglitazone was reduced. These results demonstrate that rosiglitazone-activated PPAR directly induces the transcription of NF-1, contributing to neuroprotection in neurons.